Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -195.6%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3M | $15M | $1M | — | — | — | — | — | — | — | — |
| Enterprise Value | $-6919929 | $5M | $-14449458 | — | — | — | — | — | — | — | — |
| P/E Ratio → | -0.19 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.47 | 2.79 | 0.18 | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -195.6% | -195.6% | -224.2% | -64.9% | -76.9% | -140.2% | -304.5% | -173.4% | — | -272.0% | -353.5% |
| ROA | -30.4% | -30.4% | -141.3% | -44.3% | -55.5% | -110.1% | -233.4% | -233.1% | -136.0% | -152.7% | -99.8% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
| ROCE | -38.4% | -38.4% | -232.2% | -82.4% | -107.9% | -139.6% | -302.3% | -252.4% | -190.9% | -199.2% | -181.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.02 | 0.01 | — | 0.00 | 0.01 | 0.01 | — | 2.55 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.89 | -2.00 | -1.33 | -1.53 | -1.12 | -1.39 | -1.12 | — | -2.14 | -1.16 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -5.37 | — | — | -917.09 | -387.15 | -115.82 | — |
Net cash position: cash ($10M) exceeds total debt ($210000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.93 | 1.93 | 1.94 | 3.78 | 2.85 | 7.69 | 2.89 | 6.78 | 17.39 | 2.97 | 6.00 |
| Quick Ratio | 1.93 | 1.93 | 1.94 | 3.78 | 2.85 | 7.69 | 2.89 | 6.78 | 17.39 | 2.97 | 6.00 |
| Cash Ratio | 1.82 | 1.82 | 1.94 | 3.76 | 2.83 | 7.60 | 2.73 | 6.68 | 12.99 | 2.89 | 5.83 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $2M | $705193 | $461009 | $29246 | $8767 | $6143 | $1979 | $209 | $157 | $140 |
Liquidity and clinical execution
According to recent market data, MetaVia trades at a price-to-book ratio of 0.47, which suggests that investors are heavily discounting the company's intangible assets relative to its historical valuation and the broader micro-cap biotechnology peer group currently operating in the metabolic space.
The depressed P/B multiple appears to indicate that the market assigns little value to the company's pipeline beyond its immediate cash position. This valuation suggests that investors are waiting for definitive Phase 2a clinical data before assigning any premium to the GPR119-targeted therapeutic platform.
Based on reported financial statements, the current ratio has fluctuated significantly, reaching 2.73 in 2026Q1, yet this metric may overstate the company's actual flexibility given the high, non-discretionary nature of ongoing clinical trial expenditures required to maintain the current development timeline.
While the current ratio appears superficially healthy, the lack of recurring revenue means that liquidity is entirely dependent on the timing of capital raises. The volatility in the quick ratio suggests that the company's ability to meet short-term obligations is highly sensitive to the pace of clinical trial spending.
As reported in quarterly filings, the company's days payable outstanding has shown extreme variability, ranging from 18,603 to 77,996 days, which suggests that the timing of vendor payments is likely being managed to preserve cash rather than reflecting standard operational efficiency.
This extreme fluctuation in DPO indicates that management is likely prioritizing cash conservation over standard payment cycles. Such erratic working capital management warrants further investigation, as it may signal potential friction with clinical research partners or suppliers.
Based on an analysis of the company's financial structure, the use of P/E ratios is fundamentally misapplied to MetaVia, as the firm's pre-revenue status renders earnings-based valuation metrics entirely irrelevant for assessing its true intrinsic value or future commercial potential.
Investors should instead focus on the 'Cash Runway-to-Data' ratio, which better captures the relationship between current liquidity and the timing of critical clinical milestones. Relying on traditional profitability metrics obscures the reality that the company's value is driven by clinical progress rather than current operational margins.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MTVA stock.
MetaVia Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
MetaVia Inc.'s return on equity (ROE) is -195.6%. The historical average is -200.6%.
Based on historical data, MetaVia Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.